ClinicalTrials.gg
Active, not recruitingNCT04765345RUSH1FUpdated Feb 4, 2026

Rate of Progression of PCDH15-Related Retinal Degeneration in Usher Syndrome 1F

An observational study in Retinal Degeneration, Retinitis Pigmentosa and Eye Diseases, Hereditary, sponsored by Jaeb Center for Health Research. Active, not recruiting at 10 sites in 8 countries. Open to participants aged 8 Years and older. Per ClinicalTrials.gov, last updated 2026-02-04.

Primary conditionRetinitis PigmentosaRegistry: Retinal DegenerationReclassifiedWhy we changed it
Registry
Retinal Degeneration — the first condition term the registry derived for this study.
ClinicalTrials.gg
Retinitis Pigmentosa
Why
  1. The study's listed conditions name Retinitis Pigmentosa, a narrower term within Retinal Degeneration.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Jaeb Center for Health Research · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
44
Ages
8 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 119 studies in Retinitis Pigmentosa with a site in United States — 20 open to participants now, 43 under way, 6 of them phase 3. Retinitis Pigmentosa · United States.

Enrollment
27th of 38
44 · median 73
Started
2021
with 10 others
Observational
39 of 119
11 open now
Primary completion
2027-06
later than 18 of 41 live
Registered
85th of 119
by date
Lead sponsor
3 of 119
Jaeb Center for Health Research

Among the 119 studies in Retinitis Pigmentosa with a site in United States, this one is the 27th largest by enrollment of the 38 observational ones that give a count, is one of 11 that started in 2021, is one of 39 observational ones, reaches primary completion later than 18 of the 41 other live ones, and was the 85th registered.

Retinitis Pigmentosa

281 studies on the registry are indexed under Retinitis Pigmentosa; 74 are open to participants now.

Browse Retinitis Pigmentosa studies →

Open to participants now

20 of the 119 studies in Retinitis Pigmentosa with a site in United States are open now. Recruiting first, the newest first:

15 more — sign in →

All 20 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 50 Retinitis Pigmentosa studies recruiting now, 38 (76%) set no upper age limit and 6 (12%) stop at 75 or younger; 16 take children under 18; 11 take healthy volunteers.

This study: 8 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 119 studies in Retinitis Pigmentosa with a site in United States, or all of them as a file.
02

Study summary

The overall goal of this project, co-funded by the Foundation Fighting Blindness and the USHER 1F Collaborative is to characterize the natural history of disease progression in patients with PCDH15 mutations in order to accelerate the development of outcome measures for clinical trials.

Read the detailed description

This natural history study of patients with PCDH15 disease-causing variants will accelerate the development of outcome measures for clinical trials. Sensitive, reliable outcome measures of retinal degeneration will greatly facilitate development of treatments for retinitis pigmentosa due to PCDH15 disease-causing variants. Together these approaches are expected to have an impact on understanding PCDH15 related retinal degeneration, developing experimental treatment protocols, and assessing their effectiveness.

The goals and expected impact of this natural history study are to:

  1. Describe the natural history of retinal degeneration in patients with biallelic disease-causing variants in the PCDH15 gene
  2. Contribute to the identification of sensitive structural and functional outcome measures to use for future multicenter clinical trials in PCDH15 related retinal degeneration
  3. Contribute to the identification of populations for future clinical trials of investigative treatments for PCDH15 related retinal degeneration

Study Objectives

The primary objectives of the natural history study are to:

  1. Characterize the natural history of retinal degeneration associated with biallelic pathogenic mutations in the PCDH15gene over 4 years, as measured using functional, structural, and patient-reported outcome measures
  2. Explore whether structural outcome measures can be validated as surrogates for functional outcomes in individuals with biallelic pathogenic mutations in the PCDH15 gene
  3. Explore possible risk factors (genotype, phenotype, environmental, and comorbidities) for progression of the outcome measures at 4 years in individuals with biallelic pathogenic mutations in the PCDH15 gene
  4. Explore variability and symmetry of left and right eye outcomes over 4 years in individuals with biallelic pathogenic mutations in the PCDH15 gene
03

Conditions studied

  • Retinal Degeneration
  • Retinitis Pigmentosa
  • Eye Diseases, Hereditary

Browse trials for

Keywords

  • PCDH15
04

In context

Retinitis Pigmentosa Reclassified

281 studies on the registry are indexed under Retinitis Pigmentosa; 74 are open to participants now.

This study's enrollment of 44 is below the median of 52 across 89 observational studies indexed under Retinitis Pigmentosa.

Browse Retinitis Pigmentosa studies →

Lead sponsor

Jaeb Center for Health Research is the lead sponsor of 129 studies on the registry; 16 are open to participants now.

Of its 18 completed or terminated interventional studies of FDA-regulated products, 16 (89%) have results posted.

Compared within Retinitis Pigmentosa, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Retinal Degeneration. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
8 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Study participants will be recruited from approximately 10 clinical sites worldwide. All eligible participants will be included without regard to gender, race, or ethnicity. Potential eligibility will be assessed during a routine examination by an investigator prior to obtaining informed consent, as part of usual care, through referrals from other providers or self-referral.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Participants must meet all the following inclusion criteria at the Screening Visit in order to be eligible to enroll into the genetic screening phase.

  1. Willing to participate in the study and able to communicate consent during the consent process
  2. Ability to return for all study visits over 48 months
  3. Age ≥ 8 years
  4. Not planning to enroll in an experimental clinical trial for the treatment of PCDH15 for the duration of this study
  5. Must meet one of the Genetic Screening Criteria, defined below:

    • Screening Group A: At least 2 disease-causing variants in the PCDH15 gene which are homozygous or heterozygous in trans, based on a report from a clinically certified lab (or a report from a research lab that has been pre- approved by the Genetics Committee)
    • Screening Group B: Only 1 disease-causing variant in the PCDH15 gene, based on a report from a clinically certified lab (or a report from a research lab which has been pre-approved by the Genetics Committee)
    • Screening Group C: At least 2 disease-causing variants in the PCDH15 gene which are unknown phase, based on a report from a clinically certified lab (or a report from a research lab which has been pre-approved by the Genetics Committee)

Note pertaining to all Screening Groups: if a participant has a variant(s) of unknown significance, he/she would still qualify if there is at least 1 disease-causing variant(s) on the PCDH15 gene. The Genetics Committee will review unique cases where segregation analysis is not feasible to determine eligibility.

Ocular Inclusion Criteria

Both eyes must meet all the following at the Screening Visit for a participant to be eligible to enroll into the genetic screening phase.

  1. Clinical diagnosis of retinal dystrophy
  2. Clear ocular media and adequate pupil dilation to permit good quality photographic imaging

Exclusion criteria

Exclusion Criteria:

Participants must not meet any of the following exclusion criteria at the Screening Visit in order to be eligible to enroll into the genetic screening phase.

  1. Mutations in genes that cause autosomal dominant retinitis pigmentosa (ADRP), X-linked retinitis pigmentosa (RP), or presence of biallelic mutations in autosomal recessive RP/retinal dystrophy genes other than PCDH15
  2. Expected to enter experimental treatment trial at any time during this study
  3. History of more than 1 year of cumulative treatment, at any time, with an agent associated with pigmentary retinopathy (including hydroxychloroquine, chloroquine, thioridazine, and deferoxamine)

Note: Pregnant women are not being specifically excluded from participation.

Ocular Exclusion Criteria

If either eye has any of the following at the Screening Visit, the participant is not eligible to enroll into the genetic screening phase.

  1. Current vitreous hemorrhage
  2. Current or any history of tractional or rhegmatogenous retinal detachment
  3. Current or any history of (e.g., prior to cataract or refractive surgery) spherical equivalent of the refractive error worse than -8 Diopters of myopia
  4. History of intraocular surgery (e.g., cataract surgery, vitrectomy, penetrating keratoplasty, or LASIK) within the last 3 months
  5. Current or any history of confirmed diagnosis of glaucoma (e.g., based on glaucomatous VF changes or nerve changes, or history of glaucoma filtering surgery)
  6. Current or any history of retinal vascular occlusion or proliferative diabetic retinopathy
  7. History or current evidence of ocular disease that, in the opinion of the investigator, may confound assessment of visual function
  8. History or evidence of active treatment for retinitis pigmentosa that could affect the progression of retinal degeneration, including:

    1. Any use of ocular stem cell or gene therapy
    2. Any treatment with ocriplasmin
    3. Treatment with an ophthalmic oligonucleotide within the last 9 months (last treatment date is less than 9 months prior to Screening Visit date)
    4. Treatment with any other product within five times the expected half-life of the product (time from last treatment date to Screening Visit date is at least 5 times the half-life of the given product)
    5. Treatment with Ozurdex (dexamethasone), Iluvien or Yutiq (fluocinolone acetonide) intravitreal implant
06

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
44 participants (actual)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • Vision Cohort 1

    \~25 participants with the better eye Screening Visit visual acuity ETDRS letter score of 54 or more \[approximate Snellen equivalent 20/80 or better\] and visual field diameter 10 degrees or more in every meridian of the central field. The better eye is defined as the eye with better Screening Visit ETDRS VA. If both eyes have the same VA (defined as the same Snellen equivalent), then the determination will be made at investigator discretion as the eye with better fixation or clearer ocular media to permit highest quality retinal imaging. The visual field (VF) is defined as the clinically determined kinetic VF III4e performed within the last 18 months prior to or including the Screening Visit date.

  • Vision Cohort 2

    \~15 participants with the better eye Screening Visit visual acuity ETDRS letter score of 19-53 \[approximate Snellen equivalent 20/100 - 20/400\] or (visual acuity ETDRS letter score of 54 or more \[approximate Snellen equivalent 20/80 or better\] and visual field diameter less than 10 degrees in any meridian of the central field). The better eye is defined as the eye with better Screening Visit ETDRS VA. If both eyes have the same VA (defined as the same Snellen equivalent), then the determination will be made at investigator discretion as the eye with better fixation or clearer ocular media to permit highest quality retinal imaging. The visual field (VF) is defined as the clinically determined kinetic VF III4e performed within the last 18 months prior to or including the Screening Visit date.

07

What researchers measure

Primary outcomes

  1. Change in Visual Field Sensitivity

    measured by static perimetry with quantitative, topographic analysis (Hill of Vision) and assessed by a central reading center

    Time frame: Baseline (all Vision Cohort 1 and 2 participants will complete two tests at baseline. The results will be compared according to the visual field criteria to determine if a third test is needed), 12Month, 24Month, 36Month, and 48Month

  2. Change in Best Corrected Visual Acuity

    Early Treatment of Diabetic Retinopathy Study (ETDRS) Best corrected visual acuity (BCVA) letter score as measured on the Electronic Visual Acuity (EVA) system or ETDRS charts. Letter score range values=0-100 (with higher values = better and lower values = worse.) Berkeley Rudimentary Vision Test (BRVT) will be used for patients unable to see letters.

    Time frame: Screening, Baseline, 12Month, 24Month, 36Month, and 48Month

  3. Change in Mean Retinal Sensitivity

    Measured by fundus-guided microperimetry (MP) and assessed by a central reading center at selected sites with requisite equipment.

    Time frame: Baseline (all Vision Cohort 1 and 2 participants will complete two tests at baseline. The results will be compared according to the visual field criteria to determine if a third test is needed), 12Month, 24Month, 36Month, and 48Month

  4. Change in Full-field Retinal Sensitivity

    Measured by full-field stimulus threshold (FST) testing to blue, white and red stimuli.

    Time frame: Baseline, 12Month, 24Month, 36Month, and 48Month

  5. Change in Best Corrected Low Luminance Visual Acuity (LLVA)

    Measured by Letter Score. Letter score range values=0-100 (with higher values = better and lower values = worse.)

    Time frame: Screening, Baseline, 12Month, 24Month, 36Month, and 48Month

  6. Change in Contrast Sensitivity Function (CSF)

    Measured by the CSV-1000E VectorVision chart

    Time frame: Baseline, 12Month, 24Month, 36Month, and 48Month

  7. Change in ellipsoid zone (EZ) area

    Measured by spectral domain optical coherence tomography (SD-OCT) and assessed by a central reading center.

    Time frame: Baseline, 12Month, 24Month, 36Month, and 48Month

Secondary outcomes

  1. Explore qualitative categorization of Fundus Autofluorescence (FAF) pattern

    Assessed by a central reading center.

    Time frame: Baseline, 12Month, 24Month, 36Month, and 48Month

  2. Explore quantitative measures of FAF

    Assessed by a central reading center.

    Time frame: Baseline, 12Month, 24Month, 36Month, and 48Month

Other outcomes

  1. Patient Reported Outcomes (Adults 18 years or older)

    Measured by Michigan Retinal Degeneration Questionnaire (MRDQ) MRDQ - consists of 59 items using categories: : ''None: I do not have trouble with this,'' ''A little difficulty: I notice a problem, but I do not struggle,'' ''Moderate difficulty: I struggle but I can still do this,'' ''Extreme difficulty : I struggle a lot and sometimes I cannot do this,'' and ''N/A for non-vision reasons: I do not do this.'

    Time frame: Baseline, 24Month, and 48Month

  2. Patient Reported Outcomes (Adults 18 years or older)

    Measured by Patient-Reported Outcomes Measurement Information System (PROMIS®-29)

    Time frame: Baseline, 24Month, and 48Month

  3. Patient Reported Outcomes (less than 18 years):

    L. V. Prasad-Functional Vision Questionnaire (LVP-FVQ II) The LVP-FVQ II consists of 23 items using 3 categories: 1, no difficulty; 2, some difficulty; 3, a lot of difficulty

    Time frame: Baseline, 24Month, and 48Month

08

Study locations

10 sites
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — A de-identified database is placed in the public domain on the FFB/Jaeb public website after the completion of each protocol and publication of the manuscript.

Supporting information: Study protocol, Informed consent form

Time frame: After manuscript is published

Access criteria: Users accessing data must enter an email address

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2021 (actual). Primary completion is estimated for Jun 2027, 72 months after the start.

Of 49 observational studies under Retinitis Pigmentosa, half reached primary completion within 71 months of starting (the median), counting those still running; a quarter within 23. This study's planned 72 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 2, 2021
First posted
Feb 21, 2021
StartActual
Jun 8, 2021
Primary completionEst.
Jun 30, 2027
CompletionEst.
Jun 30, 2027
Last update
Feb 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 4, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04765345
Collaborators
Usher 1F Collaborative, Marjorie C. Adams Foundation, Foundation Fighting Blindness
Responsible party
Sponsor
First posted
Feb 21, 2021
Start date
Jun 8, 2021
Primary completion
Jun 30, 2027 (estimated)
Completion
Jun 30, 2027 (estimated)
Last update
Feb 4, 2026

Study contacts

Katarina Stingl, MD
study chair · University Hospital Tuebingen

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion